Attached files
| file | filename |
|---|---|
| EX-5.1 - OPINION OF GENE A. CAPELLO - PFIZER INC | pf17591936-ex5_1.htm |
| EX-4.1 - EIGHTH SUPPLEMENTAL INDENTURE - PFIZER INC | pf17591936-ex4_1.htm |
| 8-K - CURRENT REPORT - PFIZER INC | pf17591936-8k.htm |
EXHIBIT 99.1
Pfizer
Completes Consent Solicitation
Receives
Requisite Consents for Amendments to Wyeth Indenture
NEW
YORK--(BUSINESS WIRE)--Pfizer today announced that it has received the requisite
consents to amend certain provisions of the indenture governing the following
outstanding debt securities (the Securities) of Wyeth, its wholly owned
subsidiary:
D.F.
King, the Tabulation Agent, has advised that as of the expiration of the consent
solicitation at 5:00 p.m., New York City time, on October 29, 2009, Pfizer had
received the requisite consents in respect of at least a majority in aggregate
principal amount of Securities outstanding as of the record date, 5:00 p.m. New
York City Time, October 14, 2009. As a result, Pfizer and Wyeth will enter into
a supplemental indenture to amend the indenture governing the Securities. In
addition, Pfizer will (i) issue an unconditional and irrevocable guarantee of
the prompt payment, when due, of any amounts owed in respect of the Securities
and (ii) make a payment to each holder who validly delivered its consent prior
to the expiration of the solicitation and did not revoke such consent of $1.50
for each $1,000 principal amount of Securities to which such consent
relates.
The
detailed terms and conditions of the consent solicitation are set forth in a
Consent Solicitation/Prospectus Supplement dated October 16, 2009, which has
been filed with the Securities and Exchange Commission.
Barclays
Capital acted as Solicitation Agent for the consent solicitation, and D.F. King
acted as the Information Agent and Tabulation Agent.
This
announcement is for informational purposes only and is not an offer to purchase
or sell, a solicitation of an offer to purchase or sell, or a solicitation of
consents with respect to any securities.
|
Debt
Security Description
|
CUSIP
No.
|
Aggregate
Principal Amount
|
|
6.700%
Notes due 2011
|
026609AM
|
$1,497,580,000
|
|
6.700%
Notes due 2011
|
026609AJ
|
$2,420,000
|
|
5.250%
Notes due 2013
|
983024AA
|
$1,500,000,000
|
|
5.500%
Notes due 2014
|
983024AE
|
$1,750,000,000
|
|
5.500%
Notes due 2016
|
983024AJ
|
$1,000,000,000
|
|
5.450%
Notes due 2017
|
983024AM
|
$500,000,000
|
|
7.250%
Notes due 2023
|
026609AC
|
$250,000,000
|
|
6.450%
Notes due 2024
|
983024AF
|
$500,000,000
|
|
6.500%
Notes due 2034
|
983024AG
|
$750,000,000
|
|
6.000%
Notes due 2036
|
983024AL
|
$500,000,000
|
|
5.950%
Notes due 2037
|
983024AN
|
$2,000,000,000
|
Contacts
Pfizer
Media:
Joan
Campion, 212-733-2798
or
Investor:
Suzanne
Harnett, 212-733-8009